Subscribe To
Regeneron shares up premarket after q4 revenue doubles and blows past estimates
Regeneron Pharmaceuticals Inc. shares REGN, -0.35% rose 1.8% in premarket trade Friday, after the company doubled its fourth-quarter revenue as sales ...
February 4, 2022, 6:41 am
Regeneron shares up premarket after q4 revenue doubles and blows past estimates
Regeneron Pharmaceuticals Inc. shares REGN, -0.35% rose 1.8% in premarket trade Friday, after the company doubled its fourth-quarter revenue as sales ...
February 4, 2022, 6:41 am
Regeneron quarterly profit nearly doubles on robust sales of covid-19 therapy
Regeneron Pharmaceuticals quarterly profit nearly doubled on Thursday, on strong sales of its COVID-19 antibod...
February 4, 2022, 6:38 am
Regeneron quarterly profit nearly doubles on robust sales of covid-19 therapy
Regeneron Pharmaceuticals quarterly profit nearly doubled on Thursday, on strong sales of its COVID-19 antibod...
February 4, 2022, 6:38 am
Regeneron quarterly profit nearly doubles on robust sales of covid-19 therapy
Regeneron Pharmaceuticals quarterly profit nearly doubled on Thursday, on strong sales of its COVID-19 antibod...
February 4, 2022, 6:38 am
Janssen inks over $1b pact for mersana's adc technology in three targets
Mersana Therapeutics Inc MRSN has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson�...
February 3, 2022, 1:39 pm
Janssen inks over $1b pact for mersana's adc technology in three targets
Mersana Therapeutics Inc MRSN has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson�...
February 3, 2022, 1:39 pm
Janssen inks over $1b pact for mersana's adc technology in three targets
Mersana Therapeutics Inc MRSN has announced a research collaboration and license agreement with Janssen Biotech Inc, a unit of Johnson & Johnson�...
February 3, 2022, 1:39 pm
Synaffix, macrogenics ink pact for next generation antibody-drug conjugates
Synaffix BV has entered into a technology agreement with MacroGenics Inc MGNX. Get the Inside Access Traders Are Using to Profit More and Win Big...
February 3, 2022, 1:28 pm
Synaffix, macrogenics ink pact for next generation antibody-drug conjugates
Synaffix BV has entered into a technology agreement with MacroGenics Inc MGNX. Get the Inside Access Traders Are Using to Profit More and Win Big...
February 3, 2022, 1:28 pm
Synaffix, macrogenics ink pact for next generation antibody-drug conjugates
Synaffix BV has entered into a technology agreement with MacroGenics Inc MGNX. Get the Inside Access Traders Are Using to Profit More and Win Big...
February 3, 2022, 1:28 pm
Sorrento therapeutics ceo details covishield neutralizing antibody and cancer ‘moonshot' treatment
Yahoo Finance Live's Alexis Christoforous speaks with Sorrento Therapeutics Chairman and CEO Henry Ji to discuss the CoviShield ...
February 2, 2022, 4:28 pm
Sorrento therapeutics ceo details covishield neutralizing antibody and cancer ‘moonshot' treatment
Yahoo Finance Live's Alexis Christoforous speaks with Sorrento Therapeutics Chairman and CEO Henry Ji to discuss the CoviShield ...
February 2, 2022, 4:28 pm
Sorrento therapeutics ceo details covishield neutralizing antibody and cancer ‘moonshot' treatment
Yahoo Finance Live's Alexis Christoforous speaks with Sorrento Therapeutics Chairman and CEO Henry Ji to discuss the CoviShield ...
February 2, 2022, 4:28 pm
Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab
Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...
February 1, 2022, 10:03 am
Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab
Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...
February 1, 2022, 10:03 am
Biogen exercises option to participate developing genentech's bispecific antibody, mosunetuzumab
Biogen Inc BIIB has exercised its option to participate in the development and commercialization of mosunetuzumab, a CD20xCD3 T-cell engaging bispe...
February 1, 2022, 10:03 am
Viridian therapeutics to test next-gen igf-1r antibody in thyroid eye disease
The FDA has signed off Viridian Therapeutics Inc's VRDN investigational new drug (IND) application of VRDN-002. [ALERT] Nic Chahine shares his Be...
January 31, 2022, 10:18 am
Viridian therapeutics to test next-gen igf-1r antibody in thyroid eye disease
The FDA has signed off Viridian Therapeutics Inc's VRDN investigational new drug (IND) application of VRDN-002. [ALERT] Nic Chahine shares his Be...
January 31, 2022, 10:18 am
Viridian therapeutics to test next-gen igf-1r antibody in thyroid eye disease
The FDA has signed off Viridian Therapeutics Inc's VRDN investigational new drug (IND) application of VRDN-002. [ALERT] Nic Chahine shares his Be...
January 31, 2022, 10:18 am